{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:10:14Z","timestamp":1784740214018,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,24]]},"DOI":"10.7759\/cureus.93093","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:45:49Z","timestamp":1758710749000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative Efficacy and Cycle-Wise Toxicity of Paclitaxel-Carboplatin Versus Gemcitabine-Cisplatin in Stage IV Non-small Cell Lung Cancer (NSCLC): A Quasi-experimental Study in Bangladesh"],"prefix":"10.7759","author":[{"given":"Md. Raihan","family":"Bin Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.M. Shariful","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M. Nayeem","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman Bashar A","family":"Ayub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Habibur Rahaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Lung cancer | World Health Organization. (2023). Accessed. September 23, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer."},{"key":"ref2","unstructured":"What is lung cancer? | Types of lung cancer | American Cancer Society. (2024). Accessed. September 23, 2025: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/what-is.html."},{"key":"ref3","unstructured":"Cancer | World Health Organization. (2025). Accessed. September 23, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.05.005","article-title":"Lung cancer in Bangladesh","volume":"18","author":"Islam MR","year":"2023","unstructured":"Islam MR, Siddiqua SM, Islam R, et al.. Lung cancer in Bangladesh. J Thorac Oncol. 2023, 18:972-80. 10.1016\/j.jtho.2023.05.005","journal-title":"J Thorac Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22450-8","article-title":"Global lung cancer burden attributable to air fine particulate matter and tobacco smoke exposure: spatiotemporal patterns, sociodemographic characteristics, and transnational inequalities from 1990 to 2021","volume":"25","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Wang W, Dai K, et al.. Global lung cancer burden attributable to air fine particulate matter and tobacco smoke exposure: spatiotemporal patterns, sociodemographic characteristics, and transnational inequalities from 1990 to 2021. BMC Public Health. 2025, 25:1260. 10.1186\/s12889-025-22450-8","journal-title":"BMC Public Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard D","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, et al.. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018, 29:iv192-237. 10.1093\/annonc\/mdy275","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller JH","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, et al.. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002, 346:92-8. 10.1056\/NEJMoa011954","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp352","article-title":"A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer","volume":"21","author":"Treat JA","year":"2010","unstructured":"Treat JA, Gonin R, Socinski MA, et al.. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010, 21:540-7. 10.1093\/annonc\/mdp352","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114024","article-title":"Paclitaxel therapeutic drug monitoring - International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations","volume":"202","author":"Hertz DL","year":"2024","unstructured":"Hertz DL, Joerger M, Bang YJ, et al.. Paclitaxel therapeutic drug monitoring - International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations. Eur J Cancer. 2024, 202:114024. 10.1016\/j.ejca.2024.114024","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.111079","article-title":"Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents","volume":"136","author":"Santos NA","year":"2020","unstructured":"Santos NA, Ferreira RS, Santos AC. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol. 2020, 136:111079. 10.1016\/j.fct.2019.111079","journal-title":"Food Chem Toxicol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20230389","article-title":"Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients","volume":"65","author":"Kang H","year":"2024","unstructured":"Kang H, Suh J, You D, et al.. Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients. Investig Clin Urol. 2024, 65:256-62. 10.4111\/icu.20230389","journal-title":"Investig Clin Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.11.014","article-title":"Cost-minimisation analysis comparing gemcitabine\/cisplatin, paclitaxel\/carboplatin and vinorelbine\/cisplatin in the treatment of advanced non-small cell lung cancer in Italy","volume":"48","author":"Novello S","year":"2005","unstructured":"Novello S, Kielhorn A, Stynes G, et al.. Cost-minimisation analysis comparing gemcitabine\/cisplatin, paclitaxel\/carboplatin and vinorelbine\/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer. 2005, 48:379-87. 10.1016\/j.lungcan.2004.11.014","journal-title":"Lung Cancer"},{"key":"ref13","article-title":"National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, National Academies of Sciences, Engineering, and Medicine. Cancer Care in Low-Resource Areas: Cancer Prevention and Early Detection: Workshop Summary. Washington (DC)","author":"National Cancer Policy Forum","year":"2016","unstructured":"National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, National Academies of Sciences, Engineering, and Medicine. Cancer Prevention and Early Detection: Workshop Summary. National Academies Press (US), Washington, D.C.; 2016. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK349625\/."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.187571","article-title":"Lung cancer in the Indian subcontinent","volume":"5","author":"Noronha V","year":"2016","unstructured":"Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer. 2016, 5:95-103. 10.4103\/2278-330X.187571","journal-title":"South Asian J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.9452","article-title":"Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599","volume":"25","author":"Langer C","year":"2007","unstructured":"Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol. 2007, 25:418-23. 10.1200\/JCO.2005.04.9452","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v21i8.25","article-title":"Comparison of gemcitabine\/carboplat in versus paclitaxel\/cisplatin for the management of non small cell lung cancer","volume":"21","author":"Wang W","year":"2022","unstructured":"Wang W, Li W, Dai L, Zhao L, Qu K. Comparison of gemcitabine\/carboplat in versus paclitaxel\/cisplatin for the management of non small cell lung cancer. Trop J Pharm Res. 2022, 21:1763-70. 10.4314\/tjpr.v21i8.25","journal-title":"Trop J Pharm Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref18","unstructured":"RECIST 1.1 - RECIST. (2009). Accessed. September 23, 2025: https:\/\/recist.eortc.org\/recist-1-1-2\/."},{"key":"ref19","unstructured":"Resources for Researchers. Common Terminology Criteria for Adverse Events (CTCAE) - National Cancer Institute. (2018). Accessed: September 23, 2025: https:\/\/www.cancer.gov\/research\/resources\/resource\/210."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti GV","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, et al.. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008, 26:3543-51. 10.1200\/JCO.2007.15.0375","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10059","article-title":"Lung carcinoma signaling pathways activated by smoking","volume":"30","author":"Wen J","year":"2011","unstructured":"Wen J, Fu JH, Zhang W, Guo M. Lung carcinoma signaling pathways activated by smoking. Chin J Cancer. 2011, 30:551-8. 10.5732\/cjc.011.10059","journal-title":"Chin J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta JA","year":"2019","unstructured":"Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019, 85:10.5334\/aogh.2419","journal-title":"Ann Glob Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0041","article-title":"Curative, life-extending, and palliative chemotherapy: new outcomes need new names","volume":"22","author":"Neugut AI","year":"2017","unstructured":"Neugut AI, Prigerson HG. Curative, life-extending, and palliative chemotherapy: new outcomes need new names. Oncologist. 2017, 22:883-5. 10.1634\/theoncologist.2017-0041","journal-title":"Oncologist"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.04.013","article-title":"Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: a systematic review and meta-analysis","volume":"156","author":"Horiuchi K","year":"2021","unstructured":"Horiuchi K, Sato T, Kuno T, Takagi H, Hirsch FR, Powell CA, Fukunaga K. Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2021, 156:59-67. 10.1016\/j.lungcan.2021.04.013","journal-title":"Lung Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf009","article-title":"Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated","volume":"13","author":"Chen YM","year":"2002","unstructured":"Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM, Whang-Peng J. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol. 2002, 13:108-15. 10.1093\/annonc\/mdf009","journal-title":"Ann Oncol"},{"key":"ref26","unstructured":"Cisplatin (PIM 132). (1992). Accessed. September 23, 2025: https:\/\/www.inchem.org\/documents\/pims\/pharm\/cisplat.htm."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an indian perspective","volume":"10","author":"Vaid AK","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, et al.. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an indian perspective. Front Oncol. 2020, 10:400. 10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf332","article-title":"Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial","volume":"13","author":"Rosell R","year":"2002","unstructured":"Rosell R, Gatzemeier U, Betticher DC, et al.. Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002, 13:1539-49. 10.1093\/annonc\/mdf332","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601283","article-title":"First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial","volume":"89","author":"Wachters FM","year":"2003","unstructured":"Wachters FM, Van Putten JW, Kramer H, et al.. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer. 2003, 89:1192-9. 10.1038\/sj.bjc.6601283","journal-title":"Br J Cancer"},{"key":"ref30","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda; 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548160\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404960-comparative-efficacy-and-cycle-wise-toxicity-of-paclitaxel-carboplatin-versus-gemcitabine-cisplatin-in-stage-iv-non-small-cell-lung-cancer-nsclc-a-quasi-experimental-study-in-bangladesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:45:53Z","timestamp":1758710753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404960-comparative-efficacy-and-cycle-wise-toxicity-of-paclitaxel-carboplatin-versus-gemcitabine-cisplatin-in-stage-iv-non-small-cell-lung-cancer-nsclc-a-quasi-experimental-study-in-bangladesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.93093","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}